Pancreatic Cancer Research

ResearcherThe Wistar InstituteActive in the last 2 years

Chi Van Dang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4031-2522; OpenAlex author ID A5067716685; NIH RePORTER profile ID 1870828. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 3)
Trials
0
Grants
1
Labs led
2
Collaborators
27
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 3 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 grant · 2026: 1 paper

Papers 8

  1. The HIF-2 transcription factor mediates resistance to ferroptosis in pancreatic cancer. Last author DOI 10.1016/j.molcel.2026.03.007↗
  2. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Co-author DOI 10.1126/sciimmunol.abn0704↗
  3. Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0431↗
  4. MUC-king with HIF May Rewire Pyrimidine Biosynthesis and Curb Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.06.006↗
  5. Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma". First author DOI 10.1158/1078-0432.ccr-16-2070↗
  6. Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. Last author DOI 10.1158/1078-0432.ccr-17-1115↗
  7. Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. Co-author DOI 10.1158/0008-5472.can-15-0108↗
  8. Conceptual framework for cutting the pancreatic cancer fuel supply. Last author DOI 10.1158/1078-0432.ccr-12-0041↗

Grants 1

  1. Defining metabolic adaptations within the PDAC "arid" tumor microenvironment R01CA252225↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ben Z. Stanger · 3 shared papers, 1 shared grant, 2022–2026 · strength 1.62
  2. Alexander Muir · 2 shared papers, 2022–2026 · strength 0.41
  3. Maimon E. Hubbi · 2 shared papers, 2022–2026 · strength 0.41
  4. Erin Elizabeth Hollander · 1 shared paper, 2026 · strength 0.29
  5. N.V. Rajeshkumar · 3 shared papers, 2012–2017 · strength 0.15
  6. Anirban Maitra · 3 shared papers, 2012–2017 · strength 0.15
  7. Rahul Suresh Shinde · 1 shared paper, 2022 · strength 0.13
  8. Gauri Mirji · 1 shared paper, 2022 · strength 0.13
  9. Mohamed Abdel‐Mohsen · 1 shared paper, 2022 · strength 0.13
  10. Salina Yuan · 1 shared paper, 2022 · strength 0.13
  11. Robert J. Norgard · 1 shared paper, 2022 · strength 0.13
  12. Colin S. Sheehan · 1 shared paper, 2022 · strength 0.13
  13. Ian A. Blair · 1 shared paper, 2022 · strength 0.13
  14. Yogev Sela · 1 shared paper, 2022 · strength 0.13
  15. Jinyang Li · 1 shared paper, 2022 · strength 0.13
  16. Shinichi Yabuuchi · 2 shared papers, 2015–2017 · strength 0.11
  17. Jurre J. Kamphorst · 2 shared papers, 2015–2017 · strength 0.11
  18. Manuel M. Hidalgo · 2 shared papers, 2015–2017 · strength 0.11
  19. Joshua D. Rabinowitz · 2 shared papers, 2015–2017 · strength 0.11
  20. Anne Le · 2 shared papers, 2012–2015 · strength 0.09
  21. Susan Elaine Bates · 1 shared paper, 2017 · strength 0.08
  22. Erkut Hasan Borazanci · 1 shared paper, 2017 · strength 0.08
  23. John A. Chabot · 1 shared paper, 2017 · strength 0.08
  24. Daniel D. Von Hoff · 1 shared paper, 2017 · strength 0.08
  25. Robert J. Gillies · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.